IP Library Granted Patent US 7,655,660
Granted Patent B2
US 7,655,660 · App. 11/649,822 · Granted Feb 2, 2010

Prodrugs of CC-1065 analogs

Assignee: Immunogen Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,655,660
App. No.
11/649,822
Granted
Feb 2, 2010
Kind
B2
Abstract

Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in which the prodrug also has a moiety, such as a disulfide, that can conjugate to a cell binding reagent such as an antibody. The therapeutic use of such prodrug conjugates is also described; such prodrugs of cytotoxic agents have therapeutic use because they can deliver cytotoxic prodrugs to a specific cell population for enzymatic conversion to cytoxic drugs in a targeted fashion.

Claims (9)

1. A prodrug of an analog of CC-1065 having two subunits linked by an amide bond, wherein the first subunit is a seco-CBI (cyclopropabenziindole) molecule represented by the following formula:

wherein X is halogen, and wherein the second subunit is a monoindolyl moiety of formula:

wherein R represents a moiety that enables linkage of said prodrug to a cell binding agent; R 3 , R 4 , and R 5 are each independently hydrogen, C1-C3 linear alkyl, methoxy, hydroxyl, primary amino, secondary amino, tertiary amino, or amido; and R 7 is piperazino carbamate, 4 piperidino-piperidino carbamate or phosphate.

2. The prodrug of claim 1 , wherein R comprises a thiol or a disulfide bond.

3. The prodrug of claim 1 , wherein R is selected from the group consisting of NHCO(CH 2 ) m SZ, NHCOC 6 H 4 (CH 2 ) m SZ, NHCOC 6 H 4 O(CH 2 ) m SZ, NHCO(CH 2 ) m (OCH 2 CH 2 ) n SZ, NHCOC 6 H 4 (CH 2 ) m (OCH 2 CH 2 ) n SZ, and NHCOC 6 H 4 O(CH 2 ) m (OCH 2 CH 2 ) n SZ wherein: Z represents H or SR 8 , wherein R 8 represents methyl, linear alkyl, branched alkyl, cyclic alkyl, simple or substituted aryl or heterocyclic selected from the group consisting of furyl, pyrrollyl, pyridyl, and thiophene, m represents an integer of 1 to 10, and n represents an integer of 4 to 1000.

4. The prodrug of claim 1 , wherein R is selected from the group consisting of NHCO(CH 2 ) m (OCH 2 CH 2 ) n SZ, NHCOC 6 H 4 (CH 2 ) m (OCH 2 CH 2 ) n SZ, and NHCOC 6 H 4 O(CH 2 ) m (OCH 2 CH 2 ) n SZ wherein: Z represents H or SR 8 , wherein R 8 represents methyl, linear alkyl, branched alkyl, cyclic alkyl, simple or substituted aryl or heterocyclic selected from the group consisting of furyl, pyrrollyl, pyridyl, and thiophene, m represents an integer of 1 to 10, and n represents an integer from 2 to 1000.

5. The prodrug of claim 1 , wherein R is selected from the group consisting of NHCO(CH 2 ) 2 SH, NHCO(CH 2 ) 2 SSCH 3 , NHCO(CH 2 ) 2 (OCH 2 CH 2 ) n SH and NHCO(CH 2 ) 2 (OCH 2 CH 2 ) n SSCH 3 .

6. The prodrug of claim 1 , wherein R is NHCO(CH 2 ) 2 SSCH 3 .

7. A method for treating a subject by inhibiting the growth of cells of or by killing cells of a selected cell population, comprising administering to a subject in need of treatment an effective amount of the prodrug of any one of claim 1 , 3 , 4 , 5 and 6 .

Assignments (1)
ADDRESS CHANGE Recorded May 13, 2008
From: IMMUNOGEN, INC.
To: IMMUNOGEN, INC.
Reel/Frame 020930/0905 →
Continuity (4)
Division 1121735100 · Sep 2, 2005
Division 1069285600 · Oct 27, 2003
Division 1011605300 · Apr 5, 2002
Related Publication 20070135346A1 · Jun 14, 2007